Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 134

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 134
---
 confidential information could be compromised by disclosure.

 19 

We may need to license certain intellectual property
from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, a third party may hold intellectual property, including patent rights that are important or necessary
to the development of potential new technologies or products we may license or acquire. It may be necessary for us to use the patented
or proprietary technology of third parties to commercialize potential products, in which case, we would be required to obtain a license
from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. If we were not able to
obtain a license, or we are not able to obtain a license on commercially reasonable terms, our business could be harmed, possibly materially.

Third parties may initiate legal proceedings alleging
that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect
on the success of our business. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then our commercial success depends upon our ability, and the ability of our licensors and collaborators,
to develop, manufacture, market and sell product candidates and use proprietary technologies without infringing the proprietary rights
of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become
party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to potential
new products and technology, including proceedings challenging validity before the United States Patent and Trademark Office (“USPTO”)
and/or European Patent Office (“EPO”). Third parties may assert infringement claims against us based on existing patents or
patents that may be granted in the future.

If we are found to infringe a third party’s
intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing these
products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if
we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to
us. We could be forced, including by court order, to cease commercializing any infringing technology or product. In addition, we could
be found liable for monetary damages, including treble damages and attorneys’